Head-To-Head Contrast: Corvus Pharmaceuticals (CRVS) and Brainstorm Cell Therapeutics (BCLI)

Corvus Pharmaceuticals (NASDAQ: CRVS) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional and Insider Ownership

81.1% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.1% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 46.4% of Corvus Pharmaceuticals shares are owned by insiders. Comparatively, 24.7% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Corvus Pharmaceuticals and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corvus Pharmaceuticals N/A -48.78% -44.98%
Brainstorm Cell Therapeutics N/A -76.45% -59.84%

Risk & Volatility

Corvus Pharmaceuticals has a beta of -2.39, meaning that its stock price is 339% less volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Corvus Pharmaceuticals and Brainstorm Cell Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corvus Pharmaceuticals 0 1 3 0 2.75
Brainstorm Cell Therapeutics 0 0 1 0 3.00

Corvus Pharmaceuticals presently has a consensus target price of $21.67, suggesting a potential upside of 164.23%. Brainstorm Cell Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 184.81%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Corvus Pharmaceuticals.

Valuation & Earnings

This table compares Corvus Pharmaceuticals and Brainstorm Cell Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corvus Pharmaceuticals N/A N/A -$36.37 million ($2.69) -3.05
Brainstorm Cell Therapeutics N/A N/A -$4.98 million ($0.31) -10.19

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply